<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02516319</url>
  </required_header>
  <id_info>
    <org_study_id>LFA-0001</org_study_id>
    <nct_id>NCT02516319</nct_id>
  </id_info>
  <brief_title>Liver Function Assessment - Feasibility and Dosing Study</brief_title>
  <official_title>A Feasibility Study to Determine an Adequate Dose of ICG for the Liver Function Assessment System in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiox Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiox Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to 1) determine the feasibility of using Cardiox Liver Function
      Assessment System (LFA) to measure indocyanine green (ICG) clearance; 2) determine an
      adequate dose based on LFA technology and 3) determine an adequate time period for LFA
      determination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Four cohorts of subjects will be enrolled. The fist two cohorts will receive fixed doses of
      ICG dye (2.5 mg, 5.0 mg, 7.5 mg, 10.0 mg) followed by 20 minutes of LFT monitoring. The final
      two cohorts will receive weight based doses of ICG dye (0.1 mg/kg, 0.5 mg/kg) followed by 20
      minutes of LFT monitoring. Additionally the final two cohorts will have serial blood draws
      before the ICG dose and at 5, 10, 15 and 20 minutes post ICG dose.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business decision to discontinue product development.
  </why_stopped>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ICG dye detection using the LFT system compared to serial blood sampling ethods.</measure>
    <time_frame>20 minutes post ICG dose</time_frame>
    <description>Determination of an adequate dose for the Cardiox Liver Functioning Assessment LFA system to produce liver function assessments consistent with serial blood sampling methods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICG fluorescence detection at the scaphoid fossa of the ears</measure>
    <time_frame>20 minutes post ICG dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeatability of the Cardiox LFA system to detect the ICG fluorescence in the same subjects over time.</measure>
    <time_frame>20 minutes post ICG dose</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse-event recording</measure>
    <time_frame>Two hours post ICG dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Physical Examination</measure>
    <time_frame>Up to one hour post ICG dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Up to one hour post ICG dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>Up to one hour post ICG dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Respiration</measure>
    <time_frame>Up to one hour post ICG dose</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Hepatic Failure</condition>
  <arm_group>
    <arm_group_label>Serial Blood Draws</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohorts 3 and 4 - weight based doses of ICG dye followed by serial blood draws at 5, 10, 15 and 20 minutes post ICG injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liver Funtion Test Dye Detection Monitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All cohorts receive continuous LFT monitoring post ICG injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICG Dye</intervention_name>
    <arm_group_label>Serial Blood Draws</arm_group_label>
    <arm_group_label>Liver Funtion Test Dye Detection Monitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects, aged 18 to 75 years, inclusive

          -  Informed consent documentation understood and signed.

        Exclusion Criteria:

          -  Known allergy or sensitivity to the ICG or to iodide contrast dye

          -  Pregnant women or those nursing babies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael W Jopling, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiox Corporation</affiliation>
  </overall_official>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2015</study_first_submitted>
  <study_first_submitted_qc>August 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2015</study_first_posted>
  <last_update_submitted>January 14, 2016</last_update_submitted>
  <last_update_submitted_qc>January 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

